Program
KIF18A Inhibitor ATX-295
Also written as “ATX-295” and “ATX-295 and bevacizumab (or biosimilar)”.
Its studies are mostly in Ovarian Neoplasms, led by Accent Therapeutics.
Furthest: phase 2, since Jan 18, 20251 company-led study, 1 open or runningNext primary completion: Apr 30, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Accent Therapeutics | 11 open or running | phase 2since Jan 18, 2025 | Jan 18, 2025 | Apr 30, 2027phase 2 · NCT06799065 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 18, 2025First study: phase 2 study in Ovarian NeoplasmsFirst studyNCT06799065 · 218 planned · United States
Ahead
- Apr 30, 2027Primary completion: phase 2 study in Ovarian NeoplasmsNCT06799065
TargetBeta
KIF18A →read by rule
“An orally bioavailable inhibitor of the human kinesin-like protein KIF18A, ”NCIt, by rule
Other programs on KIF18A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| KIF18A Inhibitor MEN2501rule | Menarini Group | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06799065Ovarian Neoplasms · United States | 2 | Recruiting | Apr 30, 2027 | 218 |
How it is read
Names in the registry
- “ATX-295”, 1 entry
- “ATX-295 and bevacizumab (or biosimilar)”, 1 entry
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.